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Environmental factors such as nutritional state may act on the epigenome that consequently 
contributes  to  the  metabolic  adaptation  of  cells  and  the  organisms.  The  lysine-specific 
demethylase-1 (LsD1) is a unique nuclear protein that utilizes flavin adenosine dinucleotide 
(FAD) as a cofactor. Here we show that LsD1 epigenetically regulates energy-expenditure genes 
in adipocytes depending on the cellular FAD availability. We find that the loss of LsD1 function, 
either by short interfering RnA or by selective inhibitors in adipocytes, induces a number of 
regulators of energy expenditure and mitochondrial metabolism such as PPARγ coactivator-1α 
resulting in the activation of mitochondrial respiration. In the adipose tissues from mice on a 
high-fat diet, expression of LsD1-target genes is reduced, compared with that in tissues from 
mice on a normal diet, which can be reverted by suppressing LsD1 function. our data suggest a 
novel mechanism where LsD1 regulates cellular energy balance through coupling with cellular 
FAD biosynthesis. 
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I
n response to environmental stimuli, epigenetic marks such as 
DNA and histone methylation may be dynamically added and 
removed for gene regulation during the transcriptional cycle1,2. 
Nutritional information may influence the epigenome by directly 
affecting  the  activities  of  epigenetic  modifiers3.  Notably,  it  has 
been  reported  that  nutritional  conditions  in  early  life  influence 
the susceptibility to chronic disorders, such as obesity and related 
metabolic diseases, later in life4, suggesting underlying epigenetic 
mechanisms5.  Thus,  elucidating  how  nutritional  information  is 
transferred to the epigenetic machinery for the regulation of cellular 
metabolism, and the formation of the long-term metabolic pheno-
type is of great interest.
Lysine-specific demethylase-1 (LSD1, also known as KDM1A) 
is a member of the flavin-containing amine oxidase family that, in 
general, represses transcription by removing the methyl group from 
mono-methylated and di-methylated lysine 4 of histone H3 (H3K4)6. 
LSD1 is also involved in the demethylation of H3K9 when associated 
with some nuclear receptors7, and in the demethylation of non-his-
tone proteins such as p53, Stat3 and Dnmt1 (ref. 8–10), suggesting its 
contribution to selective biological processes. Indeed, genetic ablation 
of LSD1 in mice causes embryonic lethality11, and LSD1-deficient 
embryonic stem cells had cell defects and global DNA hypomethyla-
tion10, consistent with the important functions of LSD1.
Among numerous epigenetic factors, LSD1 is unique in that it 
utilizes flavin adenosine dinucleotide (FAD) as an essential cofac-
tor for catalytic activities12. FAD serves as a coenzyme in many 
oxidative reactions including mitochondrial fatty acid β-oxidation 
and in the respiratory chain13. The majority of reported flavoen-
zymes localize to the mitochondria or cytoplasm, whereas LSD1 is 
one of a few flavoproteins in the nucleus. Another nuclear flavo-
protein is apoptosis-inducing factor (AIF) that initially localizes to 
the mitochondrial inner membrane and translocates to the nucleus 
on oxidative stress or other proapoptotic stimuli, leading to DNA 
degradation14, suggesting that AIF may transfer the mitochondrial 
metabolic information to the nucleus15. However, the biological   
significance  of  FAD-dependent  LSD1  activities  in  metabolic   
regulation remains unknown.
In this study, we present direct evidence that the inhibition of 
LSD1,  by  short  interfering  RNA  (siRNA)-mediated  knockdown 
(KD)  and  by  selective  inhibitors,  activates  energy-expenditure 
genes by transcriptional and epigenetic mechanisms in adipocytes. 
Disruption of LSD1 function resulted in the de-repression of these 
genes leading to the activation of mitochondrial respiration and 
lipolysis in adipocytes. We further found that LSD1-mediated tran-
scriptional repression is FAD-dependent, and that the disruption 
of cellular FAD synthesis exerted similar effects on the metabolic 
gene expression as the LSD1 inhibition. Importantly, the expression 
of LSD1-target genes was markedly repressed in high fat-exposed 
white adipose tissue (WAT), and could be reverted by LSD1 inhibi-
tion, indicating the involvement of LSD1 in metabolic adaptation   
in vivo. Our data shed light on an essential mechanism of energy 
utilization  that  might  explain  how  cells  determine  their  energy 
strategy depending on nutritional availability.
Results
LSD1 regulates energy-expenditure genes in adipocytes. During 
our investigations, we found that both LSD1 and its essential partner 
BHC80 (ref. 16), showed relatively high expression levels in WAT 
among metabolic tissues in mice (Fig. 1a; Supplementary Fig. S1a).   
In addition, adipogenic 3T3-L1 cells abundantly expressed BHC80, 
which was found to form a complex with LSD1 in these cells (Fig. 1b;   
Supplementary  Fig.  S1b,c).  During  adipogenesis,  an  increase 
in  mono-methylated  H3K4  was  observed,  which  is  indicative 
of  the  active  regulation  of  H3K4  methylation  in  these  cells 
(Supplementary Fig. S1d). To address the role of LSD1 function 
in  adipose  cells,  we  performed  microarray-based  expression 
analyses  in  3T3-L1  cells.  We  disrupted  LSD1  function  by  using 
specific siRNAs for LSD1 and BHC80 (Fig. 1c), as well as by using 
an LSD1 inhibitor, tranylcypromine (TC, also known as trans-2-
phenylcyclopropylamine)17–21,  in  adipocyte-differentiating  3T3-
L1 cells. TC was initially identified as an inhibitor of monoamine   
oxidases (MAO) A and B22, and was demonstrated to be a potent 
inhibitor of LSD1 (refs 17,18). In agreement with the transcriptional 
repressive activities of LSD1, 198 probe sets were commonly induced 
1.5-fold or more by LSD1-KD, BHC80-KD and TC treatment (Fig. 1d;   
Supplementary Data 1). Focusing on the probe sets upregulated by 
LSD1-KD, we found significant enrichment of the probe sets that 
were similarly upregulated by TC (P = 2.8×10 − 56 by χ2 test), while 
only a few were oppositely regulated (Fig. 1e). A similar tendency 
was observed for the co-target probes of LSD1-KD and BHC80-KD 
(P = 8.0×10 − 8 by χ2 test). To clarify the biological relevance of the 
co-target genes, we used Gene set enrichment analysis23 (Fig. 1f). 
Considering the physiological function of adipocytes, we found that 
many of the co-target genes were related to lipid metabolism and 
mitochondrial oxidative phosphorylation (OXPHOS). On the other 
hand, 95 probe sets were commonly downregulated more than 1.5-fold   
by  LSD1-KD,  BHC80-KD  and  TC.  However,  GSEA  analysis  of 
the  downregulated  genes  under  LSD1  inhibition  identified  no 
significantly enriched gene sets associated with energy metabolism 
(Fig. 1g; Supplementary Data 2).
By quantitative RT–PCR analyses, we confirmed that important 
regulators of energy metabolism (Fig. 2a), such as PPARγ coactiva-
tor-1α (PGC-1α), pyruvate dehydrogenase kinase 4 (PDK4), pro-
tein kinase A regulatory subunit 2 alpha (RIIalpha) and adipose 
triglyceride lipase (ATGL), were significantly upregulated (Fig. 2b,c; 
Supplementary Data 1). These gene products have been reported 
to have key roles in mitochondrial energy production and/or lipid 
mobilization24–27. Among them, elevated expression of PGC-1α 
is a hallmark of brown adipose tissue (BAT), which is specialized 
for consumptive metabolism for the purpose of thermogenesis28. 
Consistently, LSD1 inhibition induced the expression of fatty acid 
transporter  1  (FATP1),  a  critical  regulator  of  BAT  metabolism 
(Fig. 2b,c)29,30. The selective upregulation of the group of energy-
expenditure genes was confirmed by the use of alternative siRNA 
against LSD1 (Fig. 2d,e). We also noticed that LSD1 inhibition did 
not affect the expression of the key adipogenic factors as well as the 
drivers of brown adipogenesis (Supplementary Table S1).
As TC is also a potent MAO inhibitor, we employed selective 
LSD1 inhibitors (SLIs) to discriminate whether the activation of the 
metabolic genes is attributable to specific inactivation of the enzy-
matic activity of LSD1. We used three SLIs, S2101, S2107 and S2111, 
which are structurally related to TC, but highly potent with sub-
stantially reduced affinity to MAOs (Supplementary Fig. S2a)31. All 
SLIs showed coherent effects against LSD1-target metabolic genes, 
suggesting a strong link between the enzymatic activity of LSD1 
and energy metabolism (Fig. 2c). In addition, MAO inhibitors, par-
gyline and clorgyline17, did not activate LSD1-target genes at the 
tested concentrations (Supplementary Fig. S2b). Consistently, IC50 
values of LSD1 and MAO inhibitors correlate well with the activa-
tion of LSD1-target genes by these drugs (Supplementary Table S2). 
The expression microarray analysis, using the cells treated with SLIs, 
confirmed the selectivity of these drugs, and further emphasized the 
link between LSD1 enzymatic activity and metabolic gene regula-
tion (Supplementary Fig. S2c,d). Collectively, these results indicate 
that  LSD1  represses  expression  of  the  energy-expenditure  genes   
in adipocytes.
LSD1  epigenetically  represses  energy-expenditure  genes.  To 
investigate  the  molecular  mechanism  of  LSD1  action,  we  tested 
whether energy-expenditure genes are directly regulated by LSD1 
in  differentiating  3T3-L1  cells.  Chromatin  immunoprecipitation 
(ChIP) analysis revealed that LSD1 was specifically enriched near ARTICLE     
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the transcription start site of the PGC-1α promoter (sites 3 and 4) 
(Fig. 3a). Similarly, the selective occupancy of LSD1 was observed 
at the PDK4, FATP1 and ATGL gene promoters but not at the actB 
gene  promoter  (encoding  β-actin)  (Fig.  3b).  The  enrichment  of 
di/tri-methylated H3K4 as well as acetylated H3 was enhanced by 
LSD1-KD at LSD1-bound promoters, whereas the actB promoter 
remained unchanged (Fig. 3c,d). Moreover, Pdx1 gene, which is 
not expressed in adipose cells, showed enriched LSD1 occupancy 
and the increased H3K4 methylation after LSD1-KD, emphasiz-
ing  the  close  relationship  between  LSD1  and  H3K4  demethyla-
tion in energy-expenditure genes (Fig. 3b,c). Di-methylated H3K4   
was  enriched  at  the  PGC-1α  promoter  under  the  TC  treatment   
(Fig. 3e), consistent with the inhibition of LSD1-dependent demeth-
ylation by TC.
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Figure 1 | Genome-wide analyses of LSD1-regulated genes in adipocytes. (a) Preferential expression of LsD1 and BHC80 in WAT. Expression of LSD1 
and BHC80 mRnAs in epididymal WAT, interscapular BAT, liver and skeletal muscle. 13-week old C57BL/6J mice were fasted for 16 h before tissue 
dissection. Quantitative RT–PCR values were normalized to the expression levels of the housekeeping 36B4 gene, and are shown as means ± s.d. of four 
mice. *P < 0.05, **P < 0.01 versus WAT by student’s t-test. (b) The protein expression of LsD1 and BHC80 in adipogenic 3T3-L1 cells. The cells were 
subjected to adipogenic induction as described in methods, and were collected at the indicated time points. (c) specific siRnA-mediated knockdown of 
LsD1 and BHC80 in 3T3-L1 cells. In silico analysis, using mouse genome and EsT databases, confirmed the target specificities of the siRnAs. For western 
blot analysis, protein samples were prepared 72 h after siRnA introduction. (d) Venn diagram of the genes induced 1.5-fold or more by LsD1-knockdown 
(KD), BHC80-KD or TC treatment. siRnA-introduced or TC-treated 3T3-L1 cells were subjected to adipogenic induction for 24 h. Control siRnA or 
vehicle-treated samples were used as controls. (e) unidirectional effects of TC and BHC80-KD on LsD1-target genes. (f) Gene set enrichment analysis of 
commonly upregulated genes by LsD1-KD, BHC80-KD and TC treatment. In each panel, nominal P-values and false discovery rates (FDRs) are indicated. 
(g) Gene set enrichment analysis of commonly downregulated genes by LsD1-KD, BHC80-KD and TC treatment. significantly enriched gene sets are 
shown. nominal P-values and FDRs are indicated.ARTICLE
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We then investigated the mechanism of LSD1-mediated tran-
scriptional  repression.  LSD1-regulated  promoters  were  enriched 
with relatively high levels of methylated H3K4, consistent with their 
active transcription in adipose cells (Fig. 3f). The knockdown of 
H3K4 methyltransferase Set7/9 resulted in a partial reduction of 
methylated H3K4, suggesting that methylation equilibrium on these 
promoters was formed through active methylation/demethylation 
forces (Fig. 3g). Treatment of the cells with Trichostatin A (TSA), 
a HDAC inhibitor, induced histone H3 acetylation of the energy-
expenditure  genes  without  affecting  H3K4  methylation  status   
(Fig. 3h). This suggests that enhanced H3K4 methylation by LSD1 
inhibition was not merely a reflection of active chromatin forma-
tion, but rather indicates the direct relationship between LSD1 func-
tion and H3K4 methylation on these promoters. Typical repressive 
histone marks, methylated H3K9 and H3K27, were detected only at 
background levels on LSD1-target promoters, and were not influ-
enced by LSD1-KD (Fig. 3i).
To assess promoter silencing by LSD1, reporter assays were 
performed in which the mouse PGC-1α promoter was fused to 
the luciferase reporter gene (PGC-1α/Luc) (Fig. 4a). As expected, 
PGC-1α/Luc  activity  was  induced  by  LSD1-KD  and  BHC80-
KD  (Fig.  4b).  As  well,  TC  and  SLIs  significantly  activated  the   
PGC-1α promoter (Fig. 4c,d). We also examined the chromatin 
regulation of the PGC-1α/Luc transgene by LSD1. The ChIP assay 
confirmed that the transfected PGC-1α/Luc plasmid was engaged 
with histone H3, indicating the incorporation of the transgene 
into the nucleosome structure (Fig. 4e). TC treatment induced 
the  increase  of  H3K4  di-methylation  at  the  5′  region  of  the   
transgenic PGC-1α promoter where LSD1 was bound (Fig. 4f,g). 
Thus, energy-expenditure genes are direct targets of the LSD1-
mediated repression.
LSD1  inhibition  activates  mitochondrial  metabolism.  As  the 
LSD1 inhibition resulted in the expression of energy-expenditure 
genes  associated  with  mitochondrial  metabolism,  we  sought  to 
determine the metabolic consequences of LSD1-inhibited condi-
tions. To address this, LSD1-inhibited differentiating 3T3-L1 cells 
were stained with JC-1, a fluorescent dye that binds to the mitochon-
drial inner membrane showing green fluorescence (FL1; mitochon-
drial mass) and forms red-fluorescent aggregates depending on the 
membrane potential (FL2; respiratory activity)32. Flow cytometric 
analyses of JC-1-stained cells revealed that LSD1-KD significantly 
augmented the mitochondrial membrane potential with an elevated 
FL2/FL1 ratio that represents the respiratory activity relative to the 
mitochondrial surface area (Fig. 5a). TC and SLIs also potently aug-
mented the mitochondrial metabolism although pargyline did not 
(Fig. 5b; Supplementary Fig. 3a,b). The activated oxidative metab-
olism by LSD1 inhibition was also confirmed by measuring the 
OXPHOS capacity using a XF24 Extracellular Flux Analyzer (Sea-
horse). The maximum OXPHOS capacity was dramatically potenti-
ated by LSD1-KD (Fig. 5c). On the other hand, glycolytic activity, 
as determined by cellular lactate production, was not significantly 
affected by either LSD1-KD or TC (Supplementary Fig. S3c,d).
To characterize the metabolic properties of mature adipocytes 
under LSD1 inhibition, we used an adenovirus-based method to 
introduce short hairpin RNA (shRNA) into mature 3T3-L1 adi-
pocytes (Supplementary Fig. S4a). LSD1-KD resulted in the signifi-
cant reduction of lipid accumulation only when the lipogenesis was 
enhanced under insulin-stimulated condition (Fig. 5d). Consist-
ently, insulin-induced repression of energy-expenditure genes was 
attenuated by LSD1-KD (Supplementary Fig. 4b). In the insulin-
stimulated adipocytes, oxidative metabolism was activated by LSD1-
KD and TC treatment (Fig. 5e,f). LSD1 inhibition also reduced 
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Figure 2 | LSD1 inhibition activates genes for energy expenditure and mitochondrial metabolism in adipocytes. (a) summarized illustration of co-
target genes. Co-target genes , associated with energy expenditure and mitochondrial metabolism, are shown with cellular localization of the gene 
products. (b) Expression levels of LsD1 target genes under LsD1-KD (red bars) and BHC80-KD (blue bars). Quantitative RT–PCR values were normalized 
to the expression levels of the 36B4 gene, and are shown as the fold difference against control siRnA-introduced samples (black bars). (c) Expression 
levels of LsD1 target genes after TC (orange bars) or sLIs (s2101 (red bars), s2107 (blue bars), s2111 (white bars)) treatment. TC and sLIs were used at 
the concentrations of 10 − 4 m and 10 − 5 m, respectively. Values are shown as the fold difference against vehicle-treated samples (black bars). (d) The 
knockdown of LsD1 using an alternative siRnA (LsD1#2). (e) The effect of LsD1 siRnA#2 on the expression of newly identified LsD1-target genes. Values 
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**P < 0.01 versus control by student’s t-test.ARTICLE     
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lipid  accumulation  in  differentiating  adipocytes  (Supplementary   
Fig. 4c,d). Thus, LSD1 suppresses mitochondrial energy metabolism 
in mature adipocytes depending on the cellular energy condition.
Because  we  observed  the  activated  mitochondrial  metabo-
lism and the reduced lipid accumulation in LSD1-inhibited states 
in  adipocytes,  we  checked  whether  lipolysis  was  also  activated 
(Fig. 5g,h). Both LSD1-KD and TC treatment in insulin-stimulated 
mature  3T3-L1  adipocytes  significantly  augmented  the  lipolytic 
activity. Several types of triglyceride lipases are involved in lipolysis 
and are mainly controlled by the PKA-mediated signal cascade24,25. 
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Figure 3 | Epigenetic repression of energy-expenditure genes by LSD1. After 24-hour adipogenic induction, 3T3-L1 cells were examined for LsD1 
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Consistently, ATGL and a number of PKA-associated genes were 
upregulated  in  LSD1-inhibited  cells  (Fig.  2a–c;  Supplementary   
Data 1). Collectively, these results suggest that LSD1 suppresses 
energy  expenditure  by  inhibiting  mitochondrial  respiration  and 
lipid mobilization in adipocytes.
Loss  of  FAD  attenuates  the  gene  regulatory  activity  of  LSD1. 
To investigate the biological importance of FAD-dependent LSD1 
activities, we examined whether cellular FAD synthesis affects the 
expression of the LSD1-target genes involved in energy metabolism. 
The biosynthetic pathway from riboflavin to FAD is composed of 
two enzymes, riboflavin kinase (RFK) and FAD synthetase (FADS)33 
(Fig.  6a).  The  siRNA-mediated  knockdown  of  these  two  genes 
resulted in a mild reduction of the cellular FAD content in 3T3-L1 
cells whereas RFK-KD showing the stronger effect, as assessed by 
two different methods (Supplementary Fig. S5a,b). Expression of 
most LSD1-target genes was increased by RFK-KD while FADS-KD 
did not affect PGC-1α expression, in agreement with their effects 
on FAD production (Fig. 6b; Supplementary Fig. S5c). These results 
imply that RFK is the rate-limiting enzyme in the FAD biosynthetic 
process. It might be analogous to the case of the NAD +  (nicotina-
mide adenine dinucleotide) synthetic pathway in which Nampt, the 
first enzyme of the process, strongly affects the cellular NAD +  pool34. 
To elucidate the substantial overlap in the target genes, expression 
microarray analysis was performed using LSD1-KD and RFK-KD 
cells (Fig. 6c). A total of 132 genes were commonly induced more 
than twofold compared with the control under both knockdown 
conditions. In addition, as we focused on the probe sets upregulated 
by LSD1-KD, we found significant enrichment of the probe sets that 
were similarly upregulated by RFK-KD (P = 3.5×10 − 47 by χ2 test), 
compared with those oppositely regulated (Fig. 6d).
Earlier studies have identified the ‘GxGxxG’ sequence as a FAD-
binding consensus, one that is frequently present in FAD-dependent 
oxidases35 (Supplementary Fig. S5d). To test whether FAD-bind-
ing is required for LSD1-mediated transcriptional repression, we 
point-mutated The ‘GxGxxG’ motif located at the amino-terminal 
side to the catalytic domain of LSD1. Structural modelling of LSD1 
predicted that these mutations would deteriorate the LSD1/FAD 
interaction without affecting the overall folding of the protein36 
(Supplementary Fig. S5e,f). In the GAL4 reporter assay, wild-type 
LSD1 (GAL4-LSD1wt) suppressed the luciferase activities in a dose-
dependent manner, whereas FAD binding-defective LSD1 (GAL4-
LSD1mut) did not (Fig. 6e). We then tested whether cellular FAD   
production directly affects the repressive activity of LSD1. When 
FAD production was impaired by RFK-KD in 3T3-L1 cells, tran-
scriptional  repression  by  GAL4-LSD1wt  was  partly  abolished   
(Fig. 6f). We also used lumiflavin, a riboflavin analogue that antag-
onizes the riboflavin transport into the cells37, which reduced the 
cellular  FAD  content  (Supplementary  Fig.  S5g).  LSD1  function   
was abrogated when lumiflavin was added to the culture medium 
(Fig. 6g). More importantly, the expression of endogenous LSD1 tar-
get genes was elevated after lumiflavin treatment (Fig. 6h). Lumifla-
vin also caused the reduction of LSD1 protein without affecting the 
messenger RNA level (Supplementary Fig. S5h), raising the possibil-
ity that LSD1 protein might be unstable when it is not bound to FAD. 
Taken  together,  these  results  suggest  that  LSD1  transcriptionally 
controls energy metabolism in a cellular FAD-dependent manner.
To  address  whether  the  metabolic  environment  affects  LSD1 
activities, we examined the cellular FAD levels under the lipogenic 
conditions  in  3T3-L1  cells.  Interestingly,  cellular  FAD  content 
remarkably increased during the adipogenic differentiation (Fig. 6i). 
In addition, palmitate exposure, which has been shown to facilitate 
lipid storage and suppress PGC-1α expression38,39, also led to an 
increase of FAD content in mature 3T3-L1 adipocytes (Fig. 6j). Dur-
ing the adipogenesis, the expression of LSD1-target genes includ-
ing PGC-1α, PDK4 and FATP1 were increased, possibly reflecting 
their importance in adipocyte function (Supplementary Fig. S6a). 
The elevated FAD level may account for the activation of FAD-
demanding processes such as fatty acid oxidation and TCA cycle on 
adipogenic differentiation. Palmitate exposure slightly reduced the 
expression levels of these genes, although not statistically signifi-
cant (Supplementary Fig. S6b). The FAD content in the epididymal 
WAT from normal-diet (ND)- and high-fat-diet (HFD)-fed mice 
was measured, but no significant difference was found (Supplemen-
tary Fig. S6c). In this experiment, FAD concentration was about ten 
times lower than that of cultured adipocytes, possibly reflecting the 
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difference in the magnitude of oxidative stress or the instability of 
FAD in tissue samples. The results show that the FAD content fluc-
tuates depending on the cellular metabolic status, but further study 
is necessary to elucidate how FAD is utilized in different biological 
processes in the cell.
Effect of LSD1 inhibition on gene expression in obese WAT. To 
address the LSD1-dependent metabolic gene regulation in vivo, we 
performed gene-expression analyses in normal and obese adipose   
tissues of mice. Seven-week old C57BL/6J mice were fed a HFD for 
six weeks and acquired an obese state. Interestingly, in the adipose tis-
sues of HFD-fed mice, the expression of LSD1 and BHC80 was mark-
edly elevated compared with ND controls (Fig. 7a,b). In addition, 
the expression of the LSD1 target genes such as PGC-1α, PDK4 and 
FATP1 was significantly reduced in the obese WAT tissues (Fig. 7c),   
indicating an inverse correlation with LSD1/BHC80 expression.
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To verify the direct relationship between LSD1 function and its 
target gene expression in obese adipose tissues, we employed the   
ex vivo culture of epididymal WAT in combination with adenovirus-
mediated  depletion  of  LSD1.  We  dissected  adipose  tissues  from 
HFD-fed obese mice, and analysed the metabolic gene expression, 
3 days after adenovirus introduction (at a multiplicity of infection 
(MOI) of 1.5×108 pfu dissected tissues − 1) (Fig. 7d). In agreement 
with the above data, the loss of LSD1 increased the expression of 
some energy-expenditure genes such as PGC-1α and PDK4 in obese 
adipose tissues (Fig. 7e). Interestingly, when tissues from ND-fed 
mice were used, LSD1-KD did not induce energy-expenditure gene 
expression suggesting the energetic state-dependent action of LSD1 
(Fig. 7f). To further characterize the role of LSD1 in obese adipose 
tissues in vivo, we directly introduced the LSD1 shRNAs-expressing   
adenovirus  into  epididymal  WAT  (at  a  MOI  of  5×108 pfu  per 
mouse). Our repeated experiments using adenoviruses carrying the 
EGFP gene or LSD1 shRNAs showed the efficient introduction of 
exogenous gene into visceral adipose tissues (Fig. 7g). In agreement 
with the ex vivo studies, LSD1-KD in vivo induced relatively small 
but constant activation of the energy-expenditure genes in obese 
WAT without any evident tissue/cell defects (Fig. 7h). Thus, LSD1 
represses energy-expenditure genes in adipose tissues, possibly par-
ticipating in the establishment of the metabolic phenotypes in vivo.
To  evaluate  the  effect  of  TC  administration  on  diet-induced 
obesity  and  the  expression  of  energy-expenditure  genes  in  adi-
pose tissues in vivo, C57BL/6J mice were fed a HFD for six weeks 
in combination with an alternate-day administration of TC (10 mg 
per kg body weight) (HFD/TC) or PBS (HFD/PBS). HFD/TC mice 
showed markedly lower body weight and fat mass compared with 
the  HFD/PBS-mice,  with  an  improvement  of  the  systemic  lipid 
handling (Supplementary Fig. S7a–d). There was no difference in 
food intake among the groups (Supplementary Fig. S7e), and there 
were  no  abnormal  behaviour  or  neurological  symptoms  in  the   
TC-treated mice. Importantly, TC treatment induced the expression 
of PGC-1α and other LSD1 targets as well as BAT marker UCP-1 in 
the epididymal WAT of the HFD/TC mice (Supplementary Fig. S7f). 
Riboflavin
b a
0
0.5
1.0
1.5
2.0
Rala
tive expre
ssion
Relat
ive expra
ssion
Relat ive  l
uc acti vity
Relat
ive  l uc acti vity
FMN
FAD
RFK
FADS
FADS
RFK
PGC-1α
RIIα
FATP1
PDK4
ATGL
**
**
**
*
*
*
c
Induced >2 folds
by LSD1-KD
Induced >2 folds
by RFK-KD
132 469 428
d
Gene set: induced >2 folds by LSD1-KD
(601 genes)
RFK
KD
Induced >2 folds
Induced 1.5–2 folds
Not affected
Reduced >2 folds
Reduced 1.5–2 folds
Number of genes
0 200 400 600
0
1
2
3
h
PGC-1α
RIIα
FATP1
PDK4
ATGL
**
**
**
**
**** **
*
0
0.5
1.0
1.5
e
Mock
WT Mut
GAL4-LSD1
f
0
0.5
1.0
1.5
**
**
0
0.5
1.0
1.5
2.0
Relative l uc activity
d0 d3 d1 d7 d5 0 125 500
Palmitate (µM)
F
A
D
 
(
p
m
o
l
 
p
e
r
m
g
 
p
r
o
t
e
i
n
)
0
100
200
300
400
500
0
100
200
300
400
F
A
D
 
(
p
m
o
l
 
p
e
r
m
g
 
p
r
o
t
e
i
n
)
*
*
Mock WT Mut
GAL4-LSD1 Mock WT Mut
GAL4-LSD1
g
** **
**
i j
*
Figure 6 | Inhibition of cellular FAD synthesis blocks LSD1-mediated repression of energy-expenditure genes. (a) Biosynthesis pathway of FAD in 
mammalian cells. Flavin mononucleotide (Fmn). (b) Effect of the disruption of FAD synthesis on LsD1-target genes. RFK- (blue bars) or FADs- (white 
bars) knockdown 3T3-L1 cells were induced to differentiate for 24 h, followed by RnA extraction and quantitative RT–PCR. Values are shown as the 
fold difference against control siRnA-introduced samples (black bars). *P < 0.05, **P < 0.01 versus control siRnAs by student’s t-test. (c) Venn diagram 
of the probe sets induced by LsD1-KD and RFK-KD. (d) unidirectional effects of RFK-KD on LsD1-target genes. (e) Effect of wild-type or FAD-binding 
mutant-type LsD1 on promoter activity. GAL4-fused LsD1-expressing plasmid (0.1 or 0.5 µg) was transfected into 293T cells, together with the GAL4x5-
containing luciferase reporter construct. **P < 0.01 versus GAL4 mock by student’s t-test. (f) Effect of RFK-KD on LsD1-mediated transcriptional 
repression. Control (black bars) or RFK (blue bars) siRnA-introduced 3T3-L1 cells were transfected with indicated GAL4 plasmids 48 h before the 
luciferase measurement. *P < 0.05 between indicated conditions by student’s t-test. (g) Effect of lumiflavin treatment on LsD1-mediated transcriptional 
repression. 3T3-L1 cells were exposed to vehicle (black bars) or 50 µm lumiflavin (red bars) 48 h before the luciferase measurement. (h) Effect of 
lumiflavin on endogenous LsD1-target genes. Differentiating 3T3-L1 cells were exposed to vehicle (black bars), 25 µm (orange bars) or 50 µm (red bars) 
lumiflavin for 24 h and were subjected to RnA analyses. (i) Increase of FAD concentration during adipogenic differentiation of 3T3-L1 cells. **P < 0.01 
versus day 0 by student’s t-test. (j) Increase of FAD concentration after 24-hour palmitate exposure in mature 3T3-L1 adipocytes (day 7). Values are 
normalized to the protein concentration. *P < 0.05 versus control by student’s t-test. All histogram values are means ± s.d. of three independent samples.ARTICLE     

nATuRE CommunICATIons | DoI: 10.1038/ncomms1755
nATuRE CommunICATIons | 3:758 | DoI: 10.1038/ncomms1755 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
Collectively, these data further reinforce our finding that LSD1 is 
involved in the metabolic gene regulation.
Discussion
One of the key factors in formulating an energy strategy is envi-
ronmental  information  such  as  nutritional  availability.  As  many 
metabolism-associated genes are epigenetically regulated40, nutri-
ent-driven epigenetic factors may have important roles in forming 
metabolic phenotypes3. LSD1 is a unique demethylase that does not 
contain the jumonji domain but as a flavoenzyme does have the FAD-
dependent amine oxidase domain1. Our present study clearly indi-
cates that LSD1 negatively regulates energy expenditure that can be 
reversed by inhibiting LSD1 function and FAD biosynthesis (Fig. 8).   
Cellular FAD potentiates LSD1 to repress energy-expenditure genes 
such as PGC-1α through H3K4 demethylation in adipocytes where 
excess energy is stored as triglycerides. Moreover, our experiments 
using mature adipocytes and isolated adipose tissues revealed the 
metabolic  state-dependent  effects  of  LSD1  inhibition.  Thus,  the 
transcriptional and epigenetic regulation by FAD-dependent LSD1 
may be central in nutrient-driven metabolic adaptation.
In this study, we identified a set of energy expenditure-associated 
genes as direct targets of LSD1-mediated repression. We focused on 
the genes that were commonly induced by LSD1-KD, BHC80-KD 
and TC treatment. This criterion increased the likelihood of picking 
up genes that were directly regulated through H3K4 demethylation 
by LSD1, because BHC80 is reportedly the LSD1 partner required 
for H3K4 demethylation-dependent repression, and TC irreversibly 
inhibits the catalytic activity of LSD1 (refs 16,17). This finding was 
further confirmed by the use of SLIs with minimized nonspecific 
effects. Our microarray results also revealed the non-overlapping 
effects of LSD1-KD and BHC80-KD on the genome-wide expres-
sion profile. This suggests that in many cases, LSD1 and BHC80 
regulate gene expression independently, and that BHC80 is dispen-
sable for LSD1 function other than H3K4 demethylation. In fact, it 
is reported that BHC80 recognizes H3K4 to facilitate the demeth-
ylation by LSD1 (ref. 16), and only a fraction of LSD1 was associ-
ated with BHC80 in our experiment (Supplementary Fig. S1c). It is 
also noteworthy that reported phenotypes of LSD1- and BHC80-KO   
mice  are  distinctively  different,  indicating  the  non-overlapping   
biological function of these genes11,41.
Mechanistically, LSD1 disruption induced moderate enrichment 
of methylated H3K4 on actively transcribed promoters. Histone meth-
ylation status can be determined by the equilibrium of methylating 
and demethylating forces, and, in many cases, LSD1 demethylation   
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changes relative to nD-fed mice. **P < 0.01 versus nD-fed mice by student’s t-test. (d) Efficient introduction of adenovirus vector into cultured WAT. 
Adenovirus vector, Ad-CAG-eGFP was introduced into isolated epididymal WAT, and the eGFP expression was analysed by fluorescence microscopy. 
scale bar indicates 50 µm. (e,f) Expression of energy-expenditure genes after adenovirus-mediated knockdown of LSD1 gene in cultured WAT ex vivo. 
Epididymal WAT was dissected from either HFD- (e) or nD-fed mice (f), followed by the infection of adenoviruses, Ad-shLsD1 (red bars) or Ad-sh 
control (black bars). (g) Efficient introduction of adenoviral vectors into epididymal WAT in vivo. Adenovirus vectors carrying the eGFP gene (Ad-CAG-
eGFP) was injected into epididymal WAT after incising the outer coat of mice. Four days later, tissues were isolated for the microscopic analysis. scale bar 
indicates 2 mm. (h) Expression of energy-expenditure genes after adenovirus-mediated reduction of LsD1 in epididymal WAT in vivo. Control (black bars) 
or LsD1 (red bars) shRnA-carrying adenoviruses were directly injected into epididymal WAT of HFD-fed mice 4 days before tissue isolation. Values are 
means ± s.d. of triplicate samples. *P < 0.05, **P < 0.01 versus control shRnA by student’s t-test.ARTICLE
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activity  is  counteracted  by  the  lysine  methyltransferase  Set7/9 
(refs 9,10). Interestingly, a previous report has shown that glucose-
dependent induction of NF-κB gene expression was coincident with 
Set7/9-dependent H3K4 methylation, and was counteracted by LSD1, 
implying the possible involvement of Set7/9 in the metabolic gene 
regulation42. In our study, Set7/9-KD resulted in the partial reduction 
of H3K4 demethylation at LSD1-target promoters (Fig. 3g). Thus, it 
is possible that LSD1 fine-tunes the expression of metabolic genes so 
that the cellular energy balance can be properly maintained.
We found in this study that the restriction of cellular FAD avail-
ability weakened the LSD1-dependent transcriptional repression of 
energy-expenditure genes. LSD1, like other flavoenzymes, requires 
FAD for its catalytic activity and converts it into the reduced form, 
FADH2 (ref. 43). The catalytic activity of LSD1 may be directly 
connected to the cellular metabolic state via the fluctuation of the 
FAD/FADH2  ratio  depending  on  the  FAD  oxidation  processes 
such as fatty acid β-oxidation and the TCA cycle. Another intrigu-
ing possibility is that a physical association between the LSD1 and 
FAD production machinery determines the LSD1 activities. Indeed, 
a recent study identified the existence of RFK in the protein com-
plex containing TNFα receptor-1, in which RFK seemed to directly 
provide NADPH oxidase with FAD, facilitating the TNFα signal-
ling44. Such a mechanism might explain why even a small reduction 
in FAD content in RFK-KD and lumiflavin-treated cells was suffi-
cient for the LSD1 inhibition. In mitochondria, where the majority 
of FAD production occurs, flavoenzymes may stably associate with 
FAD even under FAD-reduced conditions33. As the FAD reserve 
for nuclear flavoenzymes is relatively small, their enzymatic activity 
could be highly sensitive to FAD restriction.
It  is  of  great  interest  that  FAD-dependent  LSD1-mediated 
demethylation  may  be  analogous  to,  but  clearly  distinct  from, 
NAD + -dependent Sirtuin 1 (Sirt1)-mediated deacetylation. Sirt1 is 
the orthologue of yeast Sir2 histone deacetylase, and promotes mito-
chondrial activation that contributes to calorie restriction-induced 
metabolic adaptation45. Regarding the regulation of the PGC-1α 
function, Sirt1 activates PGC-1α protein by deacetylating its lysine 
residue46, whereas LSD1 negatively regulates the expression of the 
PGC-1α gene. Such opposing functions of LSD1 and Sirt1 suggest 
the existence of reciprocal switches for energy homeostasis in which 
FAD and NAD +  serve as coenzymatic sensors.
Aberration of cellular energy metabolism is associated with a 
wide range of multifactor and/or polygenic diseases including obes-
ity-associated diseases, neurological disorders and cancer47–49. As 
epigenetic mechanisms are often linked to the pathogenesis of these 
diseases, the epigenetic factors responsible would be attractive as 
pharmacological therapeutic targets5,50,51. Our study depicts a novel 
mechanism of the crosstalk between energy metabolism and epige-
netic gene regulation in which the FAD-dependent LSD1 activity 
regulates energy-expenditure genes. Thus, LSD1 inhibitors may be a 
new class of epigenetic drugs that can therapeutically benefit a wide 
range of metabolic disorders.
Methods
Reagents and antibodies. Tranylcypromine hydrochloride, pargyline hydro-
chloride and lumiflavin were purchased from Sigma. Clorgyline hydrochloride 
was purchased from MP Biomedicals. The compounds S2101, S2107 and S2111 
were synthesized, as previously described31. JC-1 was purchased from Molecular 
Probes. The antibodies used were anti-LSD1 (Abcam, 1:500), anti-mono-methyl-
ated histone H3K4 (Abcam, 1:500), anti-di-methylated histone H3K4 (Millipore, 
1:500), anti-tri-methylated histone H3K4 (Millipore, 1:500), anti-acetylated histone 
H3 (Millipore), anti-pan histone H3 (Abcam, 1:2000), anti-di-methylated histone 
H3K9 (Millipore), anti-tri-methylated histone H3K9 (Millipore), anti-di-methyl-
ated histone H3K27 (Millipore), and anti-tri-methylated histone H3K27 (Mil-
lipore). Anti-BHC80 antibodies (1:500) were a generous gift from Dr Tadashi Baba 
(Tsukuba University, Japan)52. Antibodies without dilution factors were only used 
for ChIP experiments. The amount of antibodies used is described here.
Cell culture. Mouse 3T3-L1, C3H10T1/2 cells, and human 293T cells were 
cultured in DMEM (Sigma) supplemented with 10% (v/v) heat-inactivated fetal 
bovine serum and penicillin/streptomycin. Adipogenic induction of 3T3-L1 cells 
was done by a standard method53. Post-confluent cells were exposed to adipogenic 
induction reagents including 0.5 mM 3-isobutyl-1-methylxanthine (Merck), 1 µM 
dexamethasone (Wako) and 5 µg ml − 1 insulin (bovine pancreas, Sigma). For the 
experiments using differentiating adipocytes, cells were collected at 24 h after 
induction whereas for mature adipocytes, induction medium was replaced with 
maintenance medium after a 48-h-induction. Lipid accumulation was assessed  
by oil red O staining. For lipid quantification, oil red O was extracted with  
2-propanol and was subjected to colorimetric analysis at 500 nm. For the  
knockdown experiments, specific siRNAs were introduced to the cells using 
RNAiMAX reagent (Invitrogen) when they were ~50% confluent. The effective 
siRNA target sequences are listed in Supplementary Table S3.
Plasmids. To construct pGL3-PGC-1α (PGC-1α/Luc), a luciferase reporter vector 
containing a mouse PGC-1α gene promoter, the fragment (from  − 3,627 to  + 80) of 
this gene was PCR-amplified using primers containing MluI and XhoI sites at the 5′ 
and 3′ ends, respectively. The GAL4-DNA-binding domain-fused LSD1 expres-
sion vector, pcDNA3-GAL4-hLSD1wt, was generated by inserting the EcoRI-NotI 
fragment from pcDNA3-Flag-HA-hLSD1 (a gift from Dr Tadashi Baba) into the 
corresponding sites of pcDNA-GAL4mock. pcDNA3-GAL4-hLSD1mut, which 
expressed the FAD-binding motif-mutated LSD1, was prepared by site-directed 
mutagenesis. Two glycine-to-alanine mutations were introduced using the primer 
pair listed in Supplementary Table S4. GAL4-binding motifs-containing reporter 
vector (pGL3-GALx5-SNRPN) was described previously54.
Luciferase reporter assay. Luciferase reporter analyses were performed using a 
dual-luciferase reporter assay system (Promega), according to the manufacturer’s 
protocol. For PGC-1α promoter analysis, the pGL3-PGC-1α reporter vector  
was co-transfected with the reference vector pRL-TK into 3T3-L1 cells, followed  
by 24-hour adipogenic induction before luciferase measurement. The siRNAs  
were introduced 24 h before the reporter transfection. For GAL4 reporter assay, 
pcDNA-GAL4 plasmids were co-transfected with the reporter plasmid pGL3-
GALx5-SNRPN and pRL-TK into 293T or 3T3-L1 cells. After 48-h culture, the 
cells were collected for luciferase measurement. RFK siRNA was introduced 24 h 
before plasmid transfection, whereas lumiflavin was added to the culture 24 h 
before the measurement.
Gene-expression analysis. Total RNA from tissues and cells were extracted using 
Trizol reagents (Invitrogen). Complementary DNAs were produced using Super-
Script III reverse transcriptase (Invitrogen). Quantitative RT–PCR was performed 
by the SYBR green method using Thunderbird reagents (Toyobo) and ABI 7500 
Sequence Detector (Applied Biosciences). Primers used in this study are listed in 
Supplementary Table S4.
Microarray analysis. Genome-wide expression analysis was performed using 
a GeneChip Mouse Genome Array 430 2 in combination with a GeneChip 
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Figure 8 | Schematic model of LSD1 function in the metabolic gene 
regulation. schematic model for the epigenetic regulation of energy 
metabolism by LsD1. FAD-dependent LsD1 facilitates metabolic changes 
through the repression of energy-expenditure genes via H3K4 demethylation. 
This pathway may be influenced by nutrients and/or fluctuating FAD level, 
implicating the link between energetic information and the epigenome.ARTICLE     
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Hybridization, Wash and Stain Kit (Affymetrix). Microarray data were repeatedly 
confirmed at Takara Dragon Genomics Center (Ohtsu, Japan). siRNA-introduced 
and TC-treated 3T3-L1 cells were induced to differentiate for 24 h followed by  
RNA extraction and a quality check using a Bioanalyzer RNA 6000 Nano  
Assay (Agilent). Data annotation analysis was performed using GeneSpring GX 
software (Agilent). Gene set enrichment analysis was performed using GSEA  
ver. 2.0 software provided by the Broad Institute of MIT and Harvard  
(http://www.broadinstitute.org/gsea/). The accession number of the  
microarray data in GEO is GSE18600.
Chromatin immunoprecipitation and co-IP. In the ChIP experiments for detecting 
modified histones, cells were crosslinked with 1% formaldehyde55. Following the 
cell lysis, isolated nuclei were subjected to sonication for chromatin fragmentation. 
Chromatin fragments were incubated at 4 °C overnight with appropriate antibodies, 
followed by a pull-down assay using protein A/G-conjugated agarose beads. Purified 
DNAs were subjected to quantitative PCR (qPCR) using the primer sets listed in 
Supplementary Table S4. To detect LSD1 enrichment on the genomic DNAs, we 
employed a protocol for detecting indirect associations between protein and DNA56. 
Briefly, enhanced crosslinking of chromatin using formaldehyde and protein-protein 
chemical crosslinker DTBP (dimethyl 3, 3′-dithiobispropionimidate 2HCl) (Sigma) 
was performed to increase the stability of protein-DNA complexes. Chromatin frag-
mentation was done by sonication in a regular RIPA buffer containing 0.1% SDS, 
followed by immunoprecipitation, as described above. For co-IP experiments, cells 
were lysed in IP buffer (50 mM Tris–HCl pH 8.0, 5 mM EDTA 150 mM NaCl, 0.5% 
NP-40, 0.5% Triton-X100) and incubated with specific antibodies followed by the 
pull-down with protein A-sepharose beads for subsequent western blot analyses.
Generation of adenoviral vectors that express shRNA. The 65-bp oligonucle-
otides containing specific shRNA for LSD1 (5′-GATCCCACAAGGAAAGCTA 
GAAGATTCAAGAGATCTTCTAGCTTTCCTTGTGTTTTTTACGCGTG-3′; the 
target sequence is underlined), BHC80 (5′-GATCCGTTCCAGATACAGCCATT 
GTTCAAGAGACAATGGCTGTATCTGGAACTTTTTTACGCGTG-3′) and con-
trol GL3 (5′-GATCCGATTTCGAGTCGTCTTAATTTCAAGAGAATTAAGAC 
GACTCGAAATCTTTTTTACGCGTG-3′) (synthesized by TaKaRa Bio Company) 
were ligated to the BamHI and EcoRI sites of RNAi-Ready pSIREN-Shuttle Vector 
(Clontech Laboratories). and were subsequently sequenced for verification. The 
DNA fragment containing LSD1, BHC80 or GL3-specific shRNA downstream to 
the human U6 promoter was subcloned into adenoviral vector plasmid pAd.HM4, 
and was transfected to 293 cells. The generated replication-deficient adenoviral 
vector was propagated, purified and tittered, as described previously57,58.
Expression of shRNA in isolated adipose tissues. For ex vivo adipose tissue 
culture, epididymal WAT of mice was obtained, dissected into ~3-mm cubes and 
maintained in primary culture medium (DMEM/F12 (1:1) supplemented with 10% 
FBS, 100 µM ascorbic acid, 100 nM insulin and 200 pM 3, 3′, 5-triiodo l-thyro-
nine). For adenovirus infection, three tissue blocks were placed into a single well of 
48-well plate and exposed to adenovirus expressing either control or LSD1 shRNA 
at a MOI of 1.5×108 plaque-forming units (pfu) per well. Infections were repeated 
in triplicate wells for each virus.
In vivo introduction of adenoviruses. We used adenovirus transiently expressing 
LSD1 shRNAs in WAT in vivo, because LSD1-deficient mice and cells had severe 
defects11. For in vivo LSD1-knockdown experiments, adenoviruses were directly in-
jected into the epididymal WAT of HFD-fed mice. Under anaesthesia, the outer coats 
of mice were dissected at the lower part of the abdomen. In obese mice, a portion of 
epididymal WAT was visible through the peritoneum, enabling targeted injection of 
adenoviruses. Adenoviruses expressing either control or LSD1 shRNAs were injected 
into the epididymal WAT on the right side of the abdomen at a MOI of 5×108 pfu per 
mouse. Four days after injection, tissues were collected for RNA analyses.
Assessment of cellular metabolism. For the determination of mitochondrial 
metabolism, 3T3-L1 cells were stained with fluorescence dye JC-1, followed by flow 
cytometric analysis32. Following trypsinization, cells were exposed to 5 µg ml − 1 
of JC-1 in the culture medium for 15 min at 37 °C and were suspended in PBS for 
fluorescence-activated cell sorting (FACS) analysis. Green and red fluorescent 
signals detected mitochondrial mass (FL1) and mitochondrial membrane potential 
(FL2), respectively, using a FACS Canto cytometer (Becton Dickinson). Cellular 
lipolytic activity was determined by measuring the concentration of free glycerol 
released into the culture medium during the 24-h culture, using an Adipolysis  
Assay Kit (Cayman Chemical). Cellular lactate content was measured using a  
Lactate Assay Kit II (BioVision), according to the manufacturer’s instructions.  
Oxygen consumption was measured using a BD Oxygen Biosensor (BD Falcon), 
according to the manufacturer’s instructions. For the assay, adipocytes were  
dispersed into single cells by Accumax reagent (Innovative Cell Technologies)  
and resuspended in the culture medium. Cell numbers were calculated for the  
normalization of the oxygen consumption values. Oxygen consumption rate (OCR)  
values were calculated as the fold-increase during a 30-min-measurement.
Real-time measurement of OXPHOS activity. Real-time monitoring of cellular 
OXPHOS activity was performed using XF24 Extracellular Flux Analyzer (Seahorse   
Bioscience), according to the manufacturer’s instructions. siRNA-introduced  
3T3-L1 cells were inoculated on the assay culture plate and allowed to differentiate 
for 24 h before the assay. Maximum OXPHOS capacity was determined as  
previously reported with some modifications59. In brief, during the real-time  
measurement, inhibitors of respiratory chain components were serially added  
to the culture. First, the complex V inhibitor, oligomycin (1 µg ml − 1), was added 
followed by the addition of the respiratory uncoupler, carbonyl cyanide-p- 
trifluoromethoxyphenylhydrazone (FCCP) (1 µM), and then the complex I and  
III inhibitors, rotenone (100 nM) and antimycin A (10 µM). After each drug  
addition, the OCR was measured four times. The addition of FCCP accelerates 
oxygen consumption to a maximum level, whereas complex I inhibitors completely 
abolish the mitochondrial respiration. Thus, the difference in OCR between  
FCCP- and rotenone/antimycin-added states indicates the maximum OXPHOS 
capacity.
Statistical analyses. Data are presented as means ± s.d. All statistical analyses were 
performed by a two-tailed Student’s t-test, except in the microarray experiments, in 
which Pearson’s χ2 test was carried out. 
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